How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing
Article first published online: 19 JUN 2013
© 2013 American Association of Blood Banks
Special Issue: Thirty Years of Progress since Recognition of Transfusion-Associated AIDS
Volume 53, Issue 10pt2, pages 2422–2430, October 2013
How to Cite
Müller, B., Nübling, C. M., Kress, J., Roth, W. K., De Zolt, S. and Pichl, L. (2013), How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing. Transfusion, 53: 2422–2430. doi: 10.1111/trf.12298
- Issue published online: 4 OCT 2013
- Article first published online: 19 JUN 2013
- Manuscript Accepted: 3 MAY 2013
- Manuscript Revised: 26 APR 2013
- Manuscript Received: 24 JAN 2013
Nucleic acid amplification techniques (NAT) in routine blood donor screening considerably reduce the diagnostic window phase period. Nevertheless, several reports of false-negative NAT results were published. Here, four cases of human immunodeficiency virus Type 1 (HIV-1) RNA–positive blood donations that escaped detection by NAT screening are described.
Study Design and Methods
A total of 2.7 million blood donations were screened for viral infections between January 2010 and October 2012 in our German Red Cross blood donation service. Four plasma specimens with false-negative NAT results were comparatively investigated with 12 CE-marked NAT assays. In two cases of putative HIV-1 variants the target region of the NAT assay was sequenced allowing comparison with the respective primers and probes.
Most of the NAT assays used in routine blood donor screening with the 5′-long terminal repeat (LTR) as target region demonstrated deficiencies in detecting the viral variants and the low-viral-carrier donations. Sequence analysis revealed in one case a deletion of 56 nucleotides within the 5′-LTR preventing the binding of the probe accompanied by a neighbored insertion of another 52 nucleotides and several primer mismatches in another case. No false-negative results were obtained for these cases using dual-target assays. The viral load of the remaining two false-negative results was below the NAT's limit of detection.
HIV-1 is characterized by a high mutation rate and rapid generation of new viral variants. By the use of one target region for HIV-1 NAT assays there is a certain risk of false-negative results. Employing HIV-1 multi- and dual-target assays in routine blood donor screening seems to be a reasonable possibility to minimize this problem.